Integrating Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT)

Breast

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations

Miscellaneous

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination with an Anti-PD-1/PD-L1 Antibody in Participants with Advanced Non-Small Cell Lung Cancer: Lantern

A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis

Miscellaneous

A non-randomized prospective clinical trial comparing the non-inferiority of Salpingectomy to Salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [sorock]

Ovarian

M23-384: A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Lung

A Randomized Phase III Study of Systemic Therapy with or without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

Miscellaneous

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma